EyeGene Inc (185490) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-0.23x
EyeGene Inc (185490) has a Cash Flow-to-Debt Ratio of -0.23x as of March 2026, meaning its operating cash flow of ₩-3.13 Billion could theoretically repay 0% of its total liabilities (₩13.78 Billion) in one year. See financial agility of EyeGene Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.23x
Operating CF / Total Liabilities
Operating Cash Flow
₩-3.13 Billion
KRW
Total Liabilities
₩13.78 Billion
KRW
Data as of
Mar 2026
Most recent filing
EyeGene Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for EyeGene Inc across 12 annual periods. For the full cash flow conversion analysis, see EyeGene Inc cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for EyeGene Inc (2014–2025)
Year-by-year debt coverage analysis for EyeGene Inc.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.43x | ₩-5.98 Billion | ₩13.80 Billion | ▲ +46.6% |
| 2024 | -0.81x | ₩-12.17 Billion | ₩14.98 Billion | ▲ +44.3% |
| 2023 | -1.46x | ₩-20.07 Billion | ₩13.77 Billion | ▼ -7.2% |
| 2022 | -1.36x | ₩-18.57 Billion | ₩13.65 Billion | ▲ +27.4% |
| 2021 | -1.87x | ₩-30.00 Billion | ₩16.02 Billion | ▼ -505.3% |
| 2020 | -0.31x | ₩-9.75 Billion | ₩31.53 Billion | ▼ -5.1% |
| 2019 | -0.29x | ₩-8.32 Billion | ₩28.28 Billion | ▼ -20.7% |
| 2018 | -0.24x | ₩-7.48 Billion | ₩30.70 Billion | ▲ +76.5% |
| 2017 | -1.03x | ₩-6.76 Billion | ₩6.53 Billion | ▲ +59.0% |
| 2016 | -2.52x | ₩-5.99 Billion | ₩2.37 Billion | ▲ +11.8% |
| 2015 | -2.86x | ₩-4.48 Billion | ₩1.57 Billion | ▼ -102.1% |
| 2014 | -1.42x | ₩-2.39 Billion | ₩1.69 Billion | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.